

掌握復發風險 不再後悔太晚發現

非侵入式多發性骨髓瘤復發監測方案


✓ 無創抽血

✓ 高靈敏度

✓ 高特異性

✓ 穩定抗干擾

突破傳統監測方法的瓶頸



什麼是「髓易測 MyeloTrak™」？

這是一項創新血液檢測服務，透過高解析質譜及專利分析流程，可在周邊血中直接偵測M蛋白個人化特異片段，是評估微小殘存病灶（MRD）的絕佳策略。
超越傳統監測（EP）千倍靈敏，不須定序，不受抗體干擾，提早掌握復發風險，把握醫療介入的黃金期。


為什麼強調「非侵入式」？

- 僅需5ml血液，無須骨髓穿刺。
- 痛感、併發症與焦慮大幅降低。
- 支援 2~4 週高頻率追蹤，更貼近臨床需求
- 病患依從性提高，長期監測不中斷。


檢測原理是甚麼？

- **專利分析流程：**去除高豐度蛋白，保留目標 M 蛋白。
- **Bottom-up質譜鑑定：**將蛋白酶解後，以LC-MS/MS解析獨特胜肽指紋。
- **專利演算法：**比對個人化M蛋白序列，無畏背景免疫球蛋白與治療抗體干擾。
- **量化MRD指數：**提供趨勢圖與風險等級，支援臨床決策。

● 分析M蛋白特有序列



● 髓易測MyeloTrak™的檢測流程




線上諮詢Line

Non-invasive Multiple Myeloma Relapse Monitoring

- ✓ **Non-invasive Blood Draw**
- ✓ **Ultra-High Sensitivity**
- ✓ **High Specificity**
- ✓ **Robust Against Anti-body Interference**

Break Through Conventional Monitoring Limitations



What is MyeloTrak™?

MyeloTrak™ is an innovative blood-based diagnostic, leveraging high-resolution mass spectrometry and a proprietary workflow. It directly detects personalized M-protein fragments in peripheral blood, serving as an optimal strategy for assessing Minimal Residual Disease (MRD).

This assay boasts thousands-fold greater sensitivity than traditional methods (e.g., EP), requires no sequencing, and is unaffected by therapeutic antibody interference. This enables earlier relapse risk identification, ensuring timely medical intervention and seizing the golden therapeutic window for optimal patient outcomes.


Why the emphasis on "Non-invasive"?

- ◆ Painless blood draw
- ◆ Reduces discomfort/anxiety
- ◆ Enables frequent monitoring
- ◆ Boosts patient adherence


What is the detection principle behind MyeloTrak™?

- ◆ Enriches target M-proteins
- ◆ LC-MS/MS identifies unique peptides
- ◆ Algorithm quantifies personalized M-proteins
- ◆ Delivering comprehensive MRD data

Clonotypic M-protein Analysis



MyeloTrak™ Detection Workflow



LinkedIn